
EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
1 September marks the beginning of World Alzheimer’s Month. This year, we are raising awareness and encouraging our global network and beyond to ask more questions about dementia.